Metabolic syndrome is an epidemic that currently affects 47 million Americans. This number is projected to grow as the prevalence of obesity continues to rise. People with metabolic syndrome are at increased risk of coronary heart disease, other diseases related to plaque buildups in artery walls (e.g. stroke), and type 2 diabetes. Metabolic syndrome is defined as a group of risk factors that include central obesity (accumulation of excessive fat around the abdomen), abnormal cholesterol in the blood, insulin resistance (the body's inability to properly use insulin), and high blood pressure. There are three underlying causes namely obesity, physical inactivity and genetic factors.
Recently, the American Heart Association (AHA) and the National Heart, Lung, and Blood Institute published guidelines for the diagnosis and management of metabolic syndrome. The AHA recommends that therapy should target the underlying metabolic problem. The most effective way to accomplish this is by weight loss and increased physical activity, but patient compliance is poor. There are no currently available therapeutic interventions that target the underlying metabolic problem.
Kalypsys is developing KD3010, an orally administered PPARδ selective agonist, that will treat the underlying cause of metabolic syndrome.